Allergy Therapeutics Plc

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00B02LCQ05
GBP
0.11
0.11 (53400.0%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

249.3 k

Shareholding (Jun 2018)

FII

0.95%

Held by 1 FIIs

DII

99.05%

Held by 1 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROE of 1.26%

  • The company has been able to generate a Return on Equity (avg) of 1.26% signifying low profitability per unit of shareholders funds
2

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.18

3

Poor long term growth as Operating profit has grown by an annual rate -238.66% of over the last 5 years

 
4

Flat results in Dec 24

5

Risky -

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 645 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-2.41

stock-summary
Return on Equity

451.82%

stock-summary
Price to Book

-90.19

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-33.13%
0%
-33.13%
6 Months
-41.85%
0%
-41.85%
1 Year
-37.06%
0%
-37.06%
2 Years
-68.53%
0%
-68.53%
3 Years
-74.98%
0%
-74.98%
4 Years
-76.22%
0%
-76.22%
5 Years
-76.22%
0%
-76.22%

Allergy Therapeutics Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-6.40%
EBIT Growth (5y)
-238.66%
EBIT to Interest (avg)
-8.18
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.41
Sales to Capital Employed (avg)
1.66
Tax Ratio
0.11%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.95%
ROCE (avg)
5.14%
ROE (avg)
1.26%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-56.33
EV to EBIT
-13.94
EV to EBITDA
-16.16
EV to Capital Employed
41.64
EV to Sales
7.55
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-298.77%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bullish
Bullish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2018stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.95%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Allergy Therapeutics Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2023 is -18.13% vs -13.64% in Jun 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2023 is -212.32% vs -575.86% in Jun 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'23",
        "Jun'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "59.60",
          "val2": "72.80",
          "chgp": "-18.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-30.60",
          "val2": "-8.80",
          "chgp": "-247.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.20",
          "val2": "0.50",
          "chgp": "340.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.60",
          "val2": "0.40",
          "chgp": "-1,500.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-43.10",
          "val2": "-13.80",
          "chgp": "-212.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-584.90%",
          "val2": "-178.70%",
          "chgp": "-40.62%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Jun'23stock-summary
Jun'23
Jun'22
Change(%)
Net Sales
59.60
72.80
-18.13%
Operating Profit (PBDIT) excl Other Income
-30.60
-8.80
-247.73%
Interest
2.20
0.50
340.00%
Exceptional Items
-5.60
0.40
-1,500.00%
Consolidate Net Profit
-43.10
-13.80
-212.32%
Operating Profit Margin (Excl OI)
-584.90%
-178.70%
-40.62%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Jun 2023 is -18.13% vs -13.64% in Jun 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2023 is -212.32% vs -575.86% in Jun 2022

stock-summaryCompany CV
About Allergy Therapeutics Plc stock-summary
stock-summary
Allergy Therapeutics Plc
Pharmaceuticals & Biotechnology
Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company's segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World. The Company provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company's products include Pollinex Trees, Pollinex Grasses+Rye, Skin Prick Testing and diagnostic products. Its vaccines trade under various brand names, such as Pollinex Quattro, Polligoid and TA Graser Top. It uses specialized systems to process the Tyrosine to form a suspension microcrystalline tyrosine (MCT) that is combined with some of its subcutaneous injected therapies.
Company Coordinates stock-summary
Company Details
Dominion Way , WORTHING None : BN14 8SA
Registrar Details